drugset / Trial / NCT05853718
Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pharmacokinetics, efficacy and safety of TAF in HBV-infected pregnant women.
Timeline
- Start
- 2021-05-06
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tenofovir alafenamide | Small molecule | 25 mg | Oral |